Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study.
Chien-Tai Hong, Chaur-Jong Hu, Hung-Yu Lin, Dean Wu · Medicine · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 18 patients with PD (age 30-80 years), this novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity. These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 18 patients with PD (age 30-80 years). This novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity.
What the Researchers Studied
The researchers studied 18 patients with PD (age 30-80 years). The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 2 weeks. This novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 18 patients with PD (age 30-80 years). The reported sample size was 18. The study used a human clinical study. The reported treatment duration was 2 weeks.
Limitations and Safety
Safety information: This novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity. This is the first study to investigate the safety and effectiveness of the combined use of PBM and H₂ on PD.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.